BridgeBio Oncology Therapeutics (BBOT) Stock Forecast & Price Target

Compare

42 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BBOT Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

BridgeBio

Oncology Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BBOT Stock 12 Month Forecast

Average Price Target

$25.38

▲(101.55% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for BridgeBio Oncology Therapeutics in the last 3 months. The average price target is $25.38 with a high forecast of $41.00 and a low forecast of $18.00. The average price target represents a 101.55% change from the last price of $12.59.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","25":"$25","42":"$42","16.5":"$16.5","33.5":"$33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,16.5,25,33.5,42],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.08,12.458461538461538,14.836923076923078,17.215384615384615,19.593846153846155,21.972307692307695,24.35076923076923,26.729230769230767,29.10769230769231,31.486153846153847,33.864615384615384,36.24307692307693,38.621538461538464,{"y":41,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.08,11.256538461538462,12.433076923076923,13.609615384615385,14.786153846153846,15.962692307692308,17.13923076923077,18.31576923076923,19.49230769230769,20.668846153846154,21.845384615384617,23.021923076923077,24.198461538461537,{"y":25.375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.08,10.68923076923077,11.298461538461538,11.907692307692308,12.516923076923078,13.126153846153846,13.735384615384616,14.344615384615384,14.953846153846154,15.563076923076924,16.17230769230769,16.78153846153846,17.39076923076923,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.05,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.86,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.85,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.72,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.64,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.43,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.03,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.08,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$41.00

Average Price Target$25.38

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sean Laaman

Morgan Stanley

$18

Buy

42.97%

Upside

Reiterated

03/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (NASDAQ: ATAI), BridgeBio Oncology Therapeutics (NASDAQ: BBOT) and Biohaven Ltd. (NYSE: BHVN)

Andrew Berens

Leerink Partners

$41

Buy

225.66%

Upside

Reiterated

03/06/26

BridgeBio Oncology Therapeutics (BBOT) Gets a Buy from Leerink Partners

Robert Burns

H.C. Wainwright

$29

Buy

130.34%

Upside

Assigned

03/06/26

BridgeBio Oncology price target raised to $29 from $27 at H.C. WainwrightBridgeBio Oncology price target raised to $29 from $27 at H.C. Wainwright

David Nierengarten

Wedbush

$25

Buy

98.57%

Upside

Reiterated

03/06/26

Analysts Offer Insights on Healthcare Companies: BridgeBio Oncology Therapeutics (NASDAQ: BBOT), Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR) and Ardent Health Partners, Inc. (NYSE: ARDT)

Laura Prendergast

Stifel Nicolaus

$23

Buy

82.68%

Upside

Reiterated

03/06/26

Stifel Nicolaus Keeps Their Buy Rating on BridgeBio Oncology Therapeutics (BBOT)

Biren Amin

Piper Sandler

$21

Buy

66.80%

Upside

Reiterated

03/06/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), Omada Health, Inc. (NASDAQ: OMDA) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)

Matthew Biegler

Oppenheimer

$22

Buy

74.74%

Upside

Reiterated

03/06/26

BridgeBio Oncology Therapeutics (BBOT) Gets a Buy from Oppenheimer

Sean McCutcheon

Raymond James

$24

Buy

90.63%

Upside

Initiated

01/09/26

BridgeBio Oncology initiated with an Outperform at Raymond JamesBridgeBio Oncology initiated with an Outperform at Raymond James

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Initiated

08/13/25

BridgeBio Oncology initiated with an Overweight at Cantor FitzgeraldBridgeBio Oncology initiated with an Overweight at Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sean Laaman

Morgan Stanley

$18

Buy

42.97%

Upside

Reiterated

03/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (NASDAQ: ATAI), BridgeBio Oncology Therapeutics (NASDAQ: BBOT) and Biohaven Ltd. (NYSE: BHVN)

Andrew Berens

Leerink Partners

$41

Buy

225.66%

Upside

Reiterated

03/06/26

BridgeBio Oncology Therapeutics (BBOT) Gets a Buy from Leerink Partners

Robert Burns

H.C. Wainwright

$29

Buy

130.34%

Upside

Assigned

03/06/26

BridgeBio Oncology price target raised to $29 from $27 at H.C. WainwrightBridgeBio Oncology price target raised to $29 from $27 at H.C. Wainwright

David Nierengarten

Wedbush

$25

Buy

98.57%

Upside

Reiterated

03/06/26

Laura Prendergast

Stifel Nicolaus

$23

Buy

82.68%

Upside

Reiterated

03/06/26

Stifel Nicolaus Keeps Their Buy Rating on BridgeBio Oncology Therapeutics (BBOT)

Biren Amin

Piper Sandler

$21

Buy

66.80%

Upside

Reiterated

03/06/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), Omada Health, Inc. (NASDAQ: OMDA) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)

Matthew Biegler

Oppenheimer

$22

Buy

74.74%

Upside

Reiterated

03/06/26

BridgeBio Oncology Therapeutics (BBOT) Gets a Buy from Oppenheimer

Sean McCutcheon

Raymond James

$24

Buy

90.63%

Upside

Initiated

01/09/26

BridgeBio Oncology initiated with an Outperform at Raymond JamesBridgeBio Oncology initiated with an Outperform at Raymond James

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Initiated

08/13/25

BridgeBio Oncology initiated with an Overweight at Cantor FitzgeraldBridgeBio Oncology initiated with an Overweight at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Oncology Therapeutics

3 Months

xxx

Success Rate

2/4 ratings generated profit

Average Return

+1.90%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +1.90% per trade.

1 Year

Matthew BieglerOppenheimer

Success Rate

1/4 ratings generated profit

Average Return

-5.47%

a rating ―

Copying Matthew Biegler's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -5.47% per trade.

2 Years

xxx

Success Rate

1/4 ratings generated profit

Average Return

-5.47%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -5.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBOT Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BBOT has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BBOT average Analyst price target in the past 3 months is 25.38.

Each month's total comprises the sum of three months' worth of ratings.

BBOT Financial Forecast

BBOT Earnings Forecast

Next quarter’s earnings estimate for BBOT is -$0.63 with a range of -$1.07 to -$0.37. The previous quarter’s EPS was -$1.03. BBOT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year BBOT has its overall industry.

No data currently available

BBOT Sales Forecast

Next quarter’s sales forecast for BBOT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BBOT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year BBOT has its overall industry.

BBOT Stock Forecast FAQ

What is BBOT’s average 12-month price target, according to analysts?

Based on analyst ratings, BridgeBio Oncology Therapeutics’s 12-month average price target is 25.38.

What is BBOT’s upside potential, based on the analysts’ average price target?

BridgeBio Oncology Therapeutics has 101.55% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BBOT a Buy, Sell or Hold?

BridgeBio Oncology Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is BridgeBio Oncology Therapeutics’s price target?

The average price target for BridgeBio Oncology Therapeutics is 25.38. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $41.00 ,the lowest forecast is $18.00. The average price target represents 101.55% Increase from the current price of $12.59.

What do analysts say about BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of BBOT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BridgeBio Oncology Therapeutics (BBOT) Stock Forecast & Price Target

BBOT Analyst Ratings

BBOT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BridgeBio Oncology Therapeutics

BBOT Analyst Recommendation Trends

BBOT Financial Forecast

BBOT Earnings Forecast

BBOT Sales Forecast

BBOT Stock Forecast FAQ

Detailed List of Analyst Forecasts